AGH Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$806K Buy
3,203
+313
+11% +$67.3K 0.51% 43
2026
Q1
$629K Sell
2,890
-37
-1% -$8.21K 0.46% 43
2025
Q4
$669K Sell
2,927
-350
-11% -$79.7K 0.5% 38
2025
Q3
$759K Buy
3,277
+11
+0.3% +$2.24K 0.56% 35
2025
Q2
$606K Buy
3,266
+350
+12% +$65K 0.5% 38
2025
Q1
$611K Buy
2,916
+13
+0.4% +$2.53K 0.59% 34
2024
Q4
$516K Buy
+2,903
New +$534K 0.48% 47

Other funds holding ABBV

AGH Wealth Advisors's ABBV Position: Q2 2026 in Review

AGH Wealth Advisors increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $67.3K and bringing the position to 3,203 shares worth $806K. The position accounts for 0.51% of the portfolio, ranked #43.

AGH Wealth Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • AGH Wealth Advisors held 3,203 shares of AbbVie worth $806K as of Q2 2026.
  • AGH Wealth Advisors bought 313 AbbVie shares in Q2 2026, an estimated $67.3K.
  • AbbVie made up 0.51% of AGH Wealth Advisors's portfolio in Q2 2026, its #43 holding.
  • AGH Wealth Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AGH Wealth Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.